## Dr Ma'en Al-Mrayat's publications

DG. Johnston. *M. Al-Mrayat*, et al. Hypopituitarism in Adults. In Conn's Medical Therapy 2002. Edited by RE Rakel and ET Bope.

Tufton, N; Ghelani, R; Srirangalingam, U; Kumar, AV; Drake, WM; Iacovazzo, D; Skordilis, K; Berney, D; **Al-Mrayat, M**; Khoo, B; Akker, SA. SDHA mutated paragangliomas may be at high risk of metastasis. **Endocrine-Related Cancer**, 24 (7), 2017, L43-L49. 10.1530/ERC-17-0030.

*M. Al-Mrayat,* M. Vloemans. Type 2 diabetes, mortality and the obesity paradox: the weight management dilemma. Practical Diabetes. 2014. Vol 31, issue 3, pages: 96-98

*M. Al-Mrayat,* M. Vloemans. Dapagliflozin: NICE guidance for use in combination therapy for the treatment of type 2 diabetes. Practical Diabetes. 2013. Vol 30, issue 6, pages: 218-220.

*M. Al-Mrayat*, et al. Prolonged release Exenatide gets the go-ahead from NICE. Practical Diabetes VOL. 29, issue 3. Pages 86-88, April 2012.

Al-Mrayat M, et al. A new cause of neuroglycopaenia: "missing the point". Diabetic Medicine. 2004 May; 21(5):497

M. Feher; *M. Al-Mrayat*, et al. Tolerability of Prolonged-Release Metformin (Glucophage) in Individuals Intolerant to Standard Metformin -- Results From Four UK Centres. British Journal of Diabetes and Vascular Disease. 2007; 7(5):225-228

*M. Al-Mrayat*, et al. Nice guidelines for management of lipids in type 2 diabetes mellitus: a practical interpretation. Diabetes & Vascular Disease Journal. 2003 Vol 3(3): 222-227.

A. Baksi, *M. Al-Mrayat*, et al. Peer advisers compared with specialist health professionals in delivering a training Programme on self-management to people with diabetes: a randomised controlled trial. <u>Diabetic Medicine</u>, Volume 25, Number 9, September 2008, pages 1076-1082(7).

DG Johnston, *M Al-Mrayat*, et al. Some elucidation of the mechanisms of vascular disease in hypopituitarism. Clinical Endocrinol (Oxf). 2002 Aug; 57(2):159-60.

PS Sharp PS, *M. Al-Mrayat*, et al. Serum levels of vascular endothelial growth factor in diabetic subjects: the relationship with blood pressure. Diabetologia 1998 Aug; 41(8): 984-985.

*M. Al-Mrayat* on Hypoglycaemia in Clinical Diabetes. Edited by Brian Frier and Miles Fisher. 2nd Edition © 2007, John Wiley & Sons ISBN 978 0 470 01844 6 Hard cover 358 pages. Practical Diabetes International, Volume 25, Issue 1, January/February 2008, Pages: 12

Al-Mrayat M, et al. Advances in insulin therapy: a commentary. British Journal of cardiology 2003; 10: 383-384

*M. Al-Mrayat,* Diabetes, driving and risk awareness, Practical Diabetes International, Volume 24, Issue 4, Date: May 2007, Pages: 186.

*M. Al-Mrayat.* The OGTT debate continues: a pragmatic clinical approach should prevail, Practical Diabetes International, Volume 23, Issue 7, Date: September 2006, Pages: 282.

## Healthcare service related publications

- *M. Al-Mrayat*. E-health: forward strides on a path with hurdles towards an uncertain destination, Practical Diabetes International, Feb 2010, <u>Volume 27 Issue 1</u>, Page 12.
- *M. Al-Mrayat.* Towards routine use of insulin pump therapy in clinical practice, Mar2009, Practical Diabetes International, Volume 26, Issue 2, Page 49.
- *M. Al-Mrayat*. NICE guidance on insulin pump therapy: over to you!, Practical Diabetes International, October 2008, Volume 25, Issue 8, Pages: 322
- *M. Al-Mrayat.* Insulin pump therapy: does counting quality count? Practical Diabetes International Volume 25, Issue 5, Date: June 2008, Pages: 178.
- *M. Al-Mrayat*. From data collection to patient connection: a contemporary approach, Practical Diabetes International, Volume 24, Issue 8, Date: October 2007, Pages: 395.
- *M. Al-Mrayat.* Coping with diversity and adversity in diabetes: reaching out to the community a way fforward. Practical Diabetes International. 2004.

## **Selected abstracts**

Najaf Haider, Pankaj Verlekar & **Ma'en Al-Mrayat.** The role of 0900 h Cortisol level to predict response to Short Syancthen Test in hypoadrenalism. Endocrine Abstracts (2016) **44** P36 . | DOI:10.1530/endoabs.44.P36

- *M. Al-Mrayat* et al. Circulating vascular endothelial growth factor in diabetic patients. Diabetic Medicine 1997; Suppl 4; Vol.14:S39
- *M. Al-Mrayat* et al . Plasma cAMP response to glucagon as an index of tissue thyroid status: A study using T4 and T3replacement in hypothyroidism. Endocrine Abstracts 2001; 1:P227.
- **M. Al-Mrayat** et al. Bone turnover markers after a single intravenous injection of growth hormone in adults with growth hormone deficiency. Endocrine Abstracts. March 2002; Vol 3: P7.
- *M. Al-Mrayat et al.* Insulin sensitivity and lipid profile in adult hypopituitarism are independent of surrogate markers of growth hormone status. Diabetic Medicine 2002; 19(S2):78-79.
- *M. Al-Mrayat et al.* The correlation between serum insulin-like growth factor 1 levels and creatinine clearance in adults with growth hormone deficiency. Endocrine Abstracts. March 2002; Vol 3: P189.
- Ravi K *M. Al-Mrayat*, et al. Dopamine-secreting paraganglioneuroma maintain high index of suspicion Endocrine Abstracts (2006) 12 P56.
- K. Lambert & *M. Al-Mrayat*. Radioactive iodine (I<sup>131</sup>) treatment in thyrotoxicosis- audit of local experience. Endocrine Abstracts (2008) 15 P366.
- R. Matsa1, *M. Al-Mrayat*, et al.. Clinical characteristics of unplanned admissions to ICU in a DGH and predictive value of modified early warning scores (MEWS). European Society of Medicine abstract, 2009.
- G. Page, *M. Al-Mrayat*, et al . Sitagliptin a retrospective review of its effects on a local population with Type 2 Diabetes Mellitus. Diabetic Medicine abstracts, March 2009.